Günther Mårder has announced his resignation from his position as a member of the Board of RaySearch with immediate effect for personal reasons. As a result, the shareholders who previously submitted proposals to the Annual General Meeting to be held on May 7, 2026 have amended their proposals as set out below.
Proposed number of members of the Board and deputies
Shareholders representing approximately 54 percent of the total number of votes in the company propose that the number of members of the Board be four, with no deputies.
Fees to the Board
The above-mentioned shareholders propose that remuneration to board members who do not receive a salary from any Group company, shall amount to a total of SEK 1,440,000 for the period until the next Annual General Meeting, of which SEK 840,000 to be paid to the Chairman and SEK 300,000 to each of the other members of the Board elected by the General Meeting.
Election of Board members (including the Chairman of the Board) and deputies
The above-mentioned shareholders propose that Carl Filip Bergendal, Johan Löf, Britta Wallgren and Hans Wigzell be re‑elected as members of the Board, and that Hans Wigzell be re‑elected as Chairman of the Board.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB
Tel: +46 (0) 8 510 530 00
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information vsystems. RaySearch’s software has been sold to over 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.